NASDAQ · NRSN
Healthcare · Biotechnology
$7.03
Up+$0.22 (+3.06%)
Updated Sep 16, 2026, 5:22 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
NRSN closed at $7.03 after 20 trading sessions, up 1740.31% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $6.43 | $7.29 | $6.055 | $7.03 | 42.31K |
| Sep 14, 2026 | $6.80 | $7.46 | $5.60 | $6.90 | 31.3K |
| Sep 11, 2026 | $6.90 | $6.982 | $6.60 | $6.944 | 11.67K |
| Sep 10, 2026 | $7.60 | $7.736 | $6.64 | $6.64 | 34.46K |
| Sep 9, 2026 | $8.638 | $9.00 | $7.96 | $8.02 | 16.99K |
| Sep 8, 2026 | $10.20 | $10.332 | $7.20 | $8.362 | 51.21K |
| Sep 4, 2026 | $0.40 | $0.5257 | $0.36 | $0.5108 | 4.22M |
| Sep 3, 2026 | $0.449 | $0.449 | $0.40 | $0.4016 | 85.67K |
| Sep 2, 2026 | $0.417 | $0.4499 | $0.3898 | $0.4108 | 212.07K |
| Sep 1, 2026 | $0.433 | $0.4499 | $0.4099 | $0.4201 | 80.1K |
| Aug 31, 2026 | $0.45 | $0.45 | $0.4052 | $0.4267 | 167.91K |
| Aug 28, 2026 | $0.44 | $0.45 | $0.4201 | $0.4204 | 95.64K |
| Aug 27, 2026 | $0.401 | $0.439 | $0.4003 | $0.4389 | 58.93K |
| Aug 26, 2026 | $0.41 | $0.4389 | $0.39 | $0.409 | 204.41K |
| Aug 25, 2026 | $0.39 | $0.42 | $0.37 | $0.3823 | 191.1K |
| Aug 24, 2026 | $0.38 | $0.38 | $0.3613 | $0.375 | 162.68K |
| Aug 21, 2026 | $0.363 | $0.39 | $0.3512 | $0.3763 | 128.46K |
| Aug 20, 2026 | $0.3989 | $0.3989 | $0.348 | $0.3504 | 340.54K |
| Aug 19, 2026 | $0.3999 | $0.50 | $0.25 | $0.398 | 1.46M |
| Aug 18, 2026 | $0.432 | $0.432 | $0.3808 | $0.382 | 331.36K |
The latest Smart Investors Daily articles mentioning NRSN.
NRSN research
Company profile and research snapshot.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 3, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 8, 2026 | D. Boral Capital | Buy | — |
| Mar 25, 2026 | D. Boral Capital | Buy | — |
| Mar 17, 2026 | D. Boral Capital | Buy | — |
| Mar 10, 2026 | Roth Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 10, 2026
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $3.
Benzinga · Feb 18, 2026
Benzinga · Feb 18, 2026
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the
Yahoo · Feb 9, 2026
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Australian Patent Office (IP Australia) has granted Australian Patent No. 2022370513, entitled "Compositions Comprising Ciprofloxacin and Celecoxib," representing another strategic step in the continued expansion of the Company's global intellectual property protection for PrimeC.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NRSN.
